Jack Henningfield, Reginald Fant and Daniel Wang The confusing and conflicting legal status of cannabis and its active constituents can inhibit product development as companies encounter significant and unique barriers to approval and appropriate scheduling. In a complementary webinar, Jack Henningfield, Ph.D., and Daniel Wang described how the development and regulatory submission of other CNS-active... Read more »... Read More >
Development of cannabinoid-based medicines is a rapidly growing area of interest for patients with unmet needs as well as the pharmaceutical industry. The path forward, however, is fraught with technical and regulatory issues that require a thoughtful approach early and throughout the development process. At two recent medicinal cannabinoid conferences, CannMed 2017 and the 2017... Read more »... Read More >
